Form 4: UTHR CEO Sells Shares via Pre-Arranged 10b5-1 Plan

United Therapeutics Corp's Chairperson & CEO, Martine A. Rothblatt, executed a planned sale of common stock following option exercise.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), reported changes in beneficial ownership.
• On March 12, 2026, Rothblatt exercised 9,500 stock options at an exercise price of $146.03 per share.
• Concurrently, Rothblatt sold a total of 9,500 shares of common stock in multiple transactions between March 12, 2026, and March 16, 2026.
• The sales were executed at weighted average prices ranging from $531.94 to $544.80 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
• Following these transactions, Rothblatt directly holds 294 shares of common stock.
• Indirect holdings include 166 shares by spouse and 639,193 shares across various family trusts.
• Rothblatt retains 154,500 derivative securities (stock options) with an exercise price of $146.03, exercisable from March 15, 2020, and expiring on March 15, 2027.
• The 10b5-1 plan is set to continue until the earlier of the exercise of 1,734,410 stock options (expiring March 17, 2027) or December 31, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive event for the insider due to the profitable exercise of options and planned diversification, while being neutral for the company as it's a routine, pre-scheduled transaction.

Positives

• The insider's exercise of stock options and subsequent sale of shares were highly profitable, with sale prices significantly above the exercise price of $146.03.
• Transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating a systematic approach to managing equity holdings rather than opportunistic selling.

Negatives

• The Chairperson & CEO sold a substantial number of shares (9,500) from direct holdings, which could be perceived as a reduction in direct exposure to the company's stock.

Risks

• No specific risks related to the company's operations or financial health are disclosed in this Form 4 filing, as it primarily reports insider transactions.

Future Outlook

The 10b5-1 trading plan is scheduled to continue until the earlier of the exercise of 1,734,410 stock options or December 31, 2026, indicating a pre-planned strategy for managing future equity awards.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common practice for executives to manage their equity compensation and diversify their portfolios in a compliant manner. These planned sales typically have less market impact than unplanned, opportunistic sales, as they reflect pre-determined financial planning rather than a reaction to immediate company performance or outlook.

Comparison to Industry Standards

• StockSavvy.ai observes that the execution of stock option exercises and subsequent sales under a Rule 10b5-1 plan is a standard practice among executives in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors where equity compensation is a significant component of executive pay.
• While specific comparable companies or projects are not detailed in this filing, the mechanism of managing equity through a pre-arranged plan aligns with best practices for insider trading compliance and personal financial planning, similar to how executives at companies like Pfizer or Johnson & Johnson might manage their equity awards.

Related Party Transactions

• No new related party transactions are disclosed beyond the existing indirect beneficial ownership through family trusts, which are a standard disclosure for insider holdings.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned insider transaction. The sale represents a small fraction of the company's overall outstanding shares.
• Employees, Customers, Suppliers, Creditors: No direct impact from this insider transaction report.

Next Steps

• Continuation of the pre-arranged 10b5-1 trading plan until the earlier of the exercise of 1,734,410 stock options or December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Beneficial Ownership, Share Sale, CEO